As part of the deal, Senju acquires the exclusive rights to develop and commercialize microdosed therapeutics in Japan and the rest of Asia. Apart from the licensing deal,
The drug is approved for use in certain people who have chronic heart failure caused by the lower-left part of their heart not contracting well. Corlanor is indicated
According to the company, this all-oral treatment is interferon (IFN) and ribavirin (RBV)-free and will be dosed once daily. In February 2015, the company submitted a new drug
Tremelimumab is one of a number of immuno-oncology products being developed by AstraZeneca and MedImmune to harness the body’s own immune system to fight cancer. The drug stimulates
In 2010, NewLink Genetics licensed Ebola vaccine candidate from its original developer the Public Health Agency of Canada’s National Microbiology Laboratory. Merck and NewLink have entered into an
Elocta is a long-acting recombinant factor VIII Fc fusion protein product candidate designed for patients with haemophilia A. Haemophilia is an inherited condition that regulates the blood’s ability
In this new oncology venture, VIB will become a shareholder alongside ThromboGenics, which will be the majority shareholder. ThromboGenics CEO Dr Patrik De Haes said: "The formation of
The deal will improve Hi-Tech’s Dietary Supplements and OTC product offering as well as expand its distribution through APN’s established platform. The transaction accelerates international growth strategy as
The Vancomycin 10g package is an addition to the company’s Vancomycin 5g pharmacy bulk package offering. The product is indicated to treat serious or severe infections caused by
The agency has issued the Prescription Drug User Fee Act (PDUFA) goal date in December 2015 for a decision on this NDA. The NDA seeks FDA approval of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.